Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

Core Points - Eagle Pharmaceuticals, Inc. held its 2025 annual meeting of stockholders on October 17, 2025, with approximately 82% of shares represented [1] Group 1: Election of Directors - Two Class I nominees, Michael Graves and Richard Edlin, were elected to hold office until the 2027 Annual Meeting, receiving 8,113,749 and 8,053,759 votes in favor, respectively [2] - Two Class II nominees, Jennifer Simpson and Luciana Borio, were elected to hold office until the 2028 Annual Meeting, receiving 8,102,909 and 8,134,574 votes in favor, respectively [2] - The total number of broker non-votes was 1,064,408, and all nominees were successfully elected [2] Group 2: Appointment of Auditor - The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 9,011,921 votes in favor, 1,700,348 against, and 57,551 abstentions [3] - There were no broker non-votes recorded for this resolution [3] Group 3: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company involved in research and development, clinical, manufacturing, and commercial activities [4] - The company focuses on developing innovative medicines aimed at improving patients' lives, with a product portfolio that includes PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® [4] - Eagle's pipeline includes oncology and CNS/metabolic critical care product candidates targeting underserved therapeutic areas, emphasizing personalized medicine in cancer care [4]